1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect

Hormone Research

Volumn 61, Issue 1, 2004, Pages 7-16

  Lippuner, Kurt ^a   Perrelet, Romain ^a   Casez, Jean Paul ^c   Popp, Albrecht ^a   Uskokovic, Milan R ^b   Jaeger, Philippe ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Calcitriol analogs; Calcium phosphate product; Secondary hyperparathyroidism; Uremia

Indexed keywords

1,25 DIHYDROXY 16 EN 23 YNE 26,26,26,27,27,27 HEXAFLUORO 19 NORCHOLECALCIFEROL; 1,25 DIHYDROXY 16 ENECHOLECALCIFEROL; 1,25 DIHYDROXY 26,26,26,27,27,27 HEXAFLUORO 16 EN 23 YNECHOLECALCIFEROL; 9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM ION; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; UREMIA;

ANIMALS; CALCITRIOL; CALCIUM; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAPERITONEAL; MALE; PARATHYROID HORMONE; PHOSPHORUS; PHOSPHORUS, DIETARY; RATS; RATS, WISTAR; UREMIA;

EID: 1542357626     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075191     Document Type: Article

References (22)

1. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995;333:166-174.
2. 3 1alpha-hydroxylase and vitamin D synthesis. Science 1997;277:1827-1830.
3. Brown EM, Pollak M, Hebert SC: The extracellular calcium-sensing receptor: Its role in health and disease. Annu Rev Med 1998;49:15-29.
4. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985;82:4270-4273.
5. 3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986;119:2864-2866.
6. Gretz N, Meisinger E, Strauch M: Partial nephrectomy and chronic renal failure: The mature rat model. Contr Nephrol. Basel, Karger, 1988, vol 60, pp 46-55.
7. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57:3759-3764.
8. 3 analogue in transgenic mice with retinoblastoma. Arch Ophtalmol 1996;114:1396-1401.
9. 3 and prostate cancer cell proliferation in vivo. Urology 1995;46:365-369.
10. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 1990;87:3929-3932.
11. 3 on the proliferation and differentiation of avian chondrocytes: Their role in tibial dyschondroplasia. J Endocrinol 1996;148:465-474.
12. Bouillon R, Allewaert K, Xiang DZ, Tan BK, van Baelen H: Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991;6:1050-1057.
13. 3: Differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res 1990;50:6857-6864.
14. 3 and two analogues. Cancer Res 1993;53:3935-3942.
15. 3 analogues on the proliferation and differentiation of cultured human keratinocytes, calcium metabolism and the differentiation of human HL-60 cells. J Nutr Biochem 1993;4:49-57.
16. Fukagawa M, Kaname SY, Igarashi T, Ogata E, Kurokawa K: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991;39:874-881.
17. Brown AJ, Finch JL, Lopez-Hilker S, Dusso A, Ritter C, Pernalete N, Slatopolsky E: New active analogs of vitamin D with low calcemic activity. Kidney Int 1990;38:s22-s27.
18. Kubrusly M, Gagné E, Urena P, Hanrotel C, Chabanis S, Lacour B, Drüeke TB: Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 1993;44:551-556.
19. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995;26:852-860.
20. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997;30:105-112.
21. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
22. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-323.